This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Novel Cancer Treatment Combination Receives Approval To Begin First-in-Human Testing For Patients With Advanced Metastatic Melanoma

Galectin Therapeutics, the Cancer Centre at the Cliniques universitaires Saint-Luc and the Ludwig Institute for Cancer Research (LICR) announced today that they will initiate a Phase 1/2 safety and efficacy trial testing a novel treatment combination in patients with advanced metastatic melanoma. The Belgian Federal Agency of Medicine and Health Products (FAMHP) granted approval to evaluate Galectin Therapeutics’ carbohydrate-based galectin receptor inhibitor, GM-CT-01, together with an LICR peptide vaccine. The trial will enroll up to 46 patients from four clinical centers in Belgium and Luxembourg.

“This trial marks Galectin Therapeutics entry into the clinic with one of our lead programs and represents a substantial opportunity for us to learn about the broad immunotherapy potential for inhibiting galectin proteins which are over expressed by nearly all tumors,” commented Peter G. Traber, M.D., President, Chief Executive Officer and Chief Medical Officer, Galectin Therapeutics.

“Preclinical studies have shown that GM-CT-01 enhances the ability of tumor-infiltrating T-lymphocytes to kill cells. Therefore, it is our hope that combining GM-CT-01 with an anti-cancer vaccine will induce a more efficient immune response that will aid in the shrinkage of metastatic tumors in patients with advanced metastatic melanoma,” said Dr. Pierre van der Bruggen of LICR.

All patients will receive either MAGE-3.A1 or NA17.A2 injections at three-week intervals throughout the study and GM-CT-01 intravenously every three days, beginning after the third dose of the peptide vaccine. Patients with at least one superficial metastatic lesion will also receive GM-CT-01 at the site of the lesion.

Partial or complete response will serve as the efficacy endpoint for the trial. Patient enrollment will commence in early 2012, and initial safety data are expected by the end of 2012. The Cliniques universitaires Saint-Luc and LICR will fund the first stage of the trial, and the second stage will be funded through grants and/or Galectin Therapeutics funds.

Each of the two peptide vaccines has already been tested in advanced melanoma patients, either alone, with or without immunological adjuvant, or in other vaccine combinations. These vaccines were well tolerated and were associated with evidence of tumor regression in a minority of patients (5 to 20%). The GM-CT-01 compound has shown initial success in preclinical studies in improving the efficacy of T-lymphocytes in killing cells. GM-CT-01 has proven safe in 100 patients in previous human studies.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,119.45 +95.39 0.53%
S&P 500 2,119.82 +11.53 0.55%
NASDAQ 5,039.5040 +34.1130 0.68%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs